Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06611826
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-23
Brief Title:
GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Prospective Single-arm Phase II Clinical Study of GEP Gemcitabine Recombinant Human Endostatin and Carrellizumab Combined With High-low-dose Radiotherapy in Non-locally Treatable Recurrent Nasopharyngeal Carcinoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This research aims to assess both effectiveness and safety of combining R-GEP regimen comprising gemcitabine recombinant human endostatin and cerexinib with low- and high-dose radiotherapy in managing unresectable recurrent nasopharyngeal carcinoma
Detailed Description:
Eligible patients will undergo screening before enrolling in this trial The participants will receive R-GEP therapy according to specified dosing schedules over six cycles Additionally administered low-dose radiotherapy during specific cycles serves to modulate immune microenvironment while high-dose fractionated radiotherapy follows completion of GEP therapy courses Maintenance immunotherapy continues up until one year post-treatment conclusion or disease progressionFinally the participants were evaluated accordingly
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None